Application | Comment | Organism |
---|---|---|
medicine | in comparison with t-PA, plasmin shows a distinct benefit-to-risk advantage. Plasmin is equally effective as t-PA in thrombolysis and may be superior for treating thrombi in totally-occluded vessels. Whereas t-PA causes bleeding from vascular trauma sites in animals when infused at dosages used for thrombolysis (0.5-1 mg/kg), plasmin exhibits safety at therapeutic dosages. Plasmin can be used at several fold higher concentrations than is needed for thrombolysis, thereby providing a significant safety margin that is not attainable for t-PA | Oryctolagus cuniculus |
medicine | plasmin is a suitable alternative to t-PA as it causes less bleeding but has equivalent or greater thrombolytic efficacy | Homo sapiens |
Cloned (Comment) | Organism |
---|---|
- |
Homo sapiens |
Organism | UniProt | Comment | Textmining |
---|---|---|---|
Homo sapiens | - |
- |
- |
Oryctolagus cuniculus | - |
- |
- |
Substrates | Comment Substrates | Organism | Products | Comment (Products) | Rev. | Reac. |
---|---|---|---|---|---|---|
plasminogen + H2O | - |
Oryctolagus cuniculus | plasmin + ? | - |
? | |
plasminogen + H2O | patients suffering intracranial hemorrhage or cerebral infarction after receiving 100 mg t-PA for acute myocardial infarction | Homo sapiens | plasmin + ? | - |
? |
Synonyms | Comment | Organism |
---|---|---|
t-PA | - |
Homo sapiens |
t-PA | - |
Oryctolagus cuniculus |
Tissue plasminogen activator | - |
Homo sapiens |
Tissue plasminogen activator | - |
Oryctolagus cuniculus |